Active ingredients: Cangrelor
Kengrexal 50 mg powder for concentrate for solution for injection/infusion.
Powder for concentrate for solution for injection/infusion.
White to off-white lyophilised powder.
Each vial contains cangrelor tetrasodium corresponding to 50 mg cangrelor. After reconstitution 1 mL of concentrate contains 10 mg cangrelor. After dilution 1 mL of solution contains 200 micrograms cangrelor.
Excipient with known effect: Each vial contains 52.2 mg sorbitol.
For the full list of excipients, see section 6.1.
Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation in vitro and ex vivo. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signalling and platelet activation.
Sodium hydroxide (for pH-adjustment)
Powder in 10 mL glass vials (Type 1) closed with a Flurotec coated butyl rubber stopper and sealed with crimped aluminium seal.
Kengrexal is available in packs of 10 vials.
Chiesi Farmaceutici S.p.A., Via Palermo, 26/A, 43122, Parma, Italy
Date of first authorisation: 23 March 2015